Bile duct cancer Archives - Patient Worthy

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

Post author:Jessica Lynn
Post published:February 8, 2024
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Source: pixabay.com

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:September 11, 2023
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

In the United States, the FDA grants Orphan Drug designation to drugs or biologics that are intended to treat, diagnose, or prevent rare conditions. A rare condition is one…

skeeze / Pixabay

Zanidatamab Could Treat HER2 Mutated Bile Duct Cancer

Post author:Jessica Lynn
Post published:June 21, 2023
Post category:Bile duct cancer Cholangiocarcinoma

Zanidatamab is an investigational IgG1 bi-specific monoclonal antibody that targets two non-overlapping HER2 domains. HER2 is overexpressed in a variety of cancer types such as breast cancer and esophageal cancer.…

source: pixabay.com

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

Post author:Rose Duesterwald
Post published:May 23, 2023
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

For patients who were given a diagnosis of advanced, inoperable (unresectable) biliary tract cancer, an article appeared in Healio with some encouraging news. Gemcitabine and cisplatin drugs have…

source: pixabay.com

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:December 19, 2022
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Rare diseases are, by their nature, rare—and because of this, it can be difficult to spur drug development. The FDA worked to overcome this through the creation of the…

source: pixabay.com

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

Post author:James Moore
Post published:April 18, 2022
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Nelson Ambrogio had always looked up to his older brother, Daniel. He has many positive memories of growing up with him. They both shared a passion for soccer, and Nelson…

source: pixabay.com

Phase 3 Global Trial for Cholangiocarcinoma Testing a Single Agent is Well Underway

Post author:Trudy Horsting
Post published:July 30, 2021
Post category:Bile duct cancer Cholangiocarcinoma

Updates from the Phase 3 clinical trial called FIGHT-302 were just released at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer. The trial is comparing two…

source: pixabay.com

Devimistat for Biliary Cancer Granted Orphan Drug Status

Post author:Jessica Lynn
Post published:July 9, 2021
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

According to MPR, the FDA recently granted Orphan Drug designation to CPI-613 (devimistat), an investigational treatment designed for patients with biliary cancer. Altogether, "biliary cancer" can consist of bile…

source: pixabay.com

The Second Ever FDA Approved Drug for Cholangiocarcinoma (CCA)

Post author:Sunniva Bean
Post published:July 6, 2021
Post category:Bile duct cancer Cholangiocarcinoma

As reported in Fierce Pharma; BridgeBio has earned FDA approval for their new targeted cancer treatment, Truseltiq. The approval is the biotech company’s first ever approval for a cancer drug,…

source: pixabay.com

ICP-192 for Cholangiocarcinoma Granted Orphan Drug Status

Post author:Jessica Lynn
Post published:June 22, 2021
Post category:Bile duct cancer

As reported by Oncology Nursing News, gunagratinib (ICP-192) was recently granted Orphan Drug designation by the FDA. Altogether, this treatment is being evaluated as a potential treatment for patients…

stevepb / Pixabay

Truseltiq Approved for Metastatic Cholangiocarcinoma

Post author:Jessica Lynn
Post published:June 21, 2021
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

In late May 2021, the FDA granted accelerated approval to Truseltiq (infigratinib). As reported by Cure, this therapy is designed for adult patients with unresectable locally advanced, previously treated, or…

Study: Combination Therapy is an Effective Treatment for Cholangiosarcoma

Post author:Kendall Mason
Post published:August 20, 2020
Post category:Bile duct cancer Rare Disease

A study conducted at the University of Texas has discovered that combination therapy may be a viable treatment for cholangiocarcinoma with BRAF mutations. Researchers treated participants with both dabrafenib and…

source: pixabay.com

Could This Investigational Drug be the Latest Advancement for Cholangiocarcinoma?

Post author:James Moore
Post published:February 12, 2020
Post category:Bile duct cancer Rare Disease

According to a story from curetoday.com, Dr. Tara Seery is an investigator in a phase 3 trial called PROOF, and she has just one goal: finding better treatments for cholangiocarcinoma,…

source: pixabay.com

New Designations for Infigratinib, a Treatment for Cholangiocarcinoma

Post author:Kendall Mason
Post published:January 21, 2020
Post category:Bile duct cancer Rare Disease

BridgeBio Pharmaceuticals has recently announced that their drug, infigratinib, has received the Fast Track and Orphan Drug designations from the FDA. This drug is meant for the treatment of…

A Blood Test That Can Detect Seven Types of Cancer

Post author:Rose Duesterwald
Post published:June 10, 2019
Post category:Bile duct cancer Ovarian Cancer Pancreatic Cancer Stomach Cancer

Health News Digest recently published an article that describes a simple blood test called DELFI, meaning DNA evaluation of fragments for early interception. Its simplicity belies the fact that it can detect…

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

Zanidatamab Could Treat HER2 Mutated Bile Duct Cancer

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

Phase 3 Global Trial for Cholangiocarcinoma Testing a Single Agent is Well Underway

Devimistat for Biliary Cancer Granted Orphan Drug Status

The Second Ever FDA Approved Drug for Cholangiocarcinoma (CCA)

ICP-192 for Cholangiocarcinoma Granted Orphan Drug Status

Truseltiq Approved for Metastatic Cholangiocarcinoma

Study: Combination Therapy is an Effective Treatment for Cholangiosarcoma

Could This Investigational Drug be the Latest Advancement for Cholangiocarcinoma?

New Designations for Infigratinib, a Treatment for Cholangiocarcinoma

A Blood Test That Can Detect Seven Types of Cancer

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More